FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030751454> ?p ?o ?g. }

• W2030751454 endingPage "1260" @default.
• W2030751454 startingPage "1253" @default.
• W2030751454 abstract "Lymphokine-activated killer (LAK) cell function can be generated in peripheral blood mononuclear cells (PBMC) after brief exposure of high dose interleukin-2 (IL-2) over the course of 1 or 2 days' culture in plain culture medium (IL-2-pulsed PBMC). The aim of the present study was to investigate the ability of granulocyte-macrophage-colony stimulating factor (GM-CSF) to augment LAK induction in low dose IL-2-pulsed PBMC derived from patients with cancer undergoing immunotherapy with IL-2.Peripheral blood mononuclear cells were collected from patients with cancer receiving a 5-day cycle of local (intraperitoneal or intrapleural) infusions with IL-2. The cells were incubated with IL-2 in the presence or absence of GM-CSF for 1 hour and then tested as effectors against allogeneic tumor cells and LAK-sensitive cell lines.Granulocyte-macrophage-colony stimulating factor at doses between 10 and 100 ng/ml was synergized with low dose IL-2 (100 IU/ml) in the generation of LAK activity in PBMC. Lymphokine-activated killer cell-mediated cytotoxicity derived from PBMC cultures incubated with IL-2 and GM-CSF was significantly higher (up to three-fold) compared with that generated with IL-2 alone. The GM-CSF-induced enhanced LAK activity was maintained when tested at day 5. GM-CSF increased the percentages of IL-2 receptor (R) positive (+) and CD8+ cells in the IL-2-pulsed PBMC. In contrast to CD56+ cells, highly purified CD8+ cells isolated from PBMC pulsed with IL-2 and GM-CSF responded with increased LAK activity, thus representing the cell-type that mediates the augmenting effect of GM-CSF. Major histocompatibility complex (MHC) molecules or the CD3 surface antigens were not involved in the GM-CSF-mediated enhancement of LAK induction because anti-MHC class I and class II monoclonal antibodies (MoAb) or MoAb against the CD3 molecules remained without any effect in this system. The GM-CSF-mediated LAK-enhancement was IL-2-dependent because MoAb against IL-2 receptor completely inhibited the generation of LAK activity.The use of GM-CSF for the enhancement of IL-2-induced LAK activity in 1 hour cultures may improve clinical results in cancer immunotherapy. In addition, implementation of this procedure could eliminate the high cost of cell culture which usually accompanies IL-2/LAK cell therapy as well as eliminate the known toxic side effects associated with this kind of therapy." @default.
• W2030751454 created "2016-06-24" @default.
• W2030751454 creator A5010280271 @default.
• W2030751454 creator A5011732363 @default.
• W2030751454 creator A5017750493 @default.
• W2030751454 creator A5020898963 @default.
• W2030751454 creator A5022974046 @default.
• W2030751454 creator A5041944228 @default.
• W2030751454 creator A5046712486 @default.
• W2030751454 date "1995-10-01" @default.
• W2030751454 modified "2023-09-23" @default.
• W2030751454 title "Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage–colony stimulating factor" @default.
• W2030751454 cites W1593137160 @default.
• W2030751454 cites W1964215240 @default.
• W2030751454 cites W1978353704 @default.
• W2030751454 cites W1981919340 @default.
• W2030751454 cites W2014487380 @default.
• W2030751454 cites W2022019386 @default.
• W2030751454 cites W2035890003 @default.
• W2030751454 cites W2036275492 @default.
• W2030751454 cites W2044163005 @default.
• W2030751454 cites W2047624824 @default.
• W2030751454 cites W2049822454 @default.
• W2030751454 cites W2050106089 @default.
• W2030751454 cites W2060148643 @default.
• W2030751454 cites W2069027822 @default.
• W2030751454 cites W2078089070 @default.
• W2030751454 cites W2102076751 @default.
• W2030751454 cites W2141298931 @default.
• W2030751454 cites W2313477330 @default.
• W2030751454 cites W2322553446 @default.
• W2030751454 cites W2326245275 @default.
• W2030751454 cites W2326695376 @default.
• W2030751454 cites W277709121 @default.
• W2030751454 cites W300828146 @default.
• W2030751454 cites W4244591305 @default.
• W2030751454 doi "https://doi.org/10.1002/1097-0142(19951001)76:7<1253::aid-cncr2820760724>3.0.co;2-f" @default.
• W2030751454 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8630906" @default.
• W2030751454 hasPublicationYear "1995" @default.
• W2030751454 type Work @default.
• W2030751454 sameAs 2030751454 @default.
• W2030751454 citedByCount "27" @default.
• W2030751454 countsByYear W20307514542021 @default.
• W2030751454 crossrefType "journal-article" @default.
• W2030751454 hasAuthorship W2030751454A5010280271 @default.
• W2030751454 hasAuthorship W2030751454A5011732363 @default.
• W2030751454 hasAuthorship W2030751454A5017750493 @default.
• W2030751454 hasAuthorship W2030751454A5020898963 @default.
• W2030751454 hasAuthorship W2030751454A5022974046 @default.
• W2030751454 hasAuthorship W2030751454A5041944228 @default.
• W2030751454 hasAuthorship W2030751454A5046712486 @default.
• W2030751454 hasBestOaLocation W20307514541 @default.
• W2030751454 hasConcept C129374314 @default.
• W2030751454 hasConcept C137061746 @default.
• W2030751454 hasConcept C167672396 @default.
• W2030751454 hasConcept C202751555 @default.
• W2030751454 hasConcept C203014093 @default.
• W2030751454 hasConcept C2777371288 @default.
• W2030751454 hasConcept C2777478134 @default.
• W2030751454 hasConcept C2777983669 @default.
• W2030751454 hasConcept C2778690821 @default.
• W2030751454 hasConcept C28651165 @default.
• W2030751454 hasConcept C49382859 @default.
• W2030751454 hasConcept C55493867 @default.
• W2030751454 hasConcept C71924100 @default.
• W2030751454 hasConcept C86803240 @default.
• W2030751454 hasConcept C8891405 @default.
• W2030751454 hasConceptScore W2030751454C129374314 @default.
• W2030751454 hasConceptScore W2030751454C137061746 @default.
• W2030751454 hasConceptScore W2030751454C167672396 @default.
• W2030751454 hasConceptScore W2030751454C202751555 @default.
• W2030751454 hasConceptScore W2030751454C203014093 @default.
• W2030751454 hasConceptScore W2030751454C2777371288 @default.
• W2030751454 hasConceptScore W2030751454C2777478134 @default.
• W2030751454 hasConceptScore W2030751454C2777983669 @default.
• W2030751454 hasConceptScore W2030751454C2778690821 @default.
• W2030751454 hasConceptScore W2030751454C28651165 @default.
• W2030751454 hasConceptScore W2030751454C49382859 @default.
• W2030751454 hasConceptScore W2030751454C55493867 @default.
• W2030751454 hasConceptScore W2030751454C71924100 @default.
• W2030751454 hasConceptScore W2030751454C86803240 @default.
• W2030751454 hasConceptScore W2030751454C8891405 @default.
• W2030751454 hasIssue "7" @default.
• W2030751454 hasLocation W20307514541 @default.
• W2030751454 hasLocation W20307514542 @default.
• W2030751454 hasOpenAccess W2030751454 @default.
• W2030751454 hasPrimaryLocation W20307514541 @default.
• W2030751454 hasRelatedWork W17427955 @default.
• W2030751454 hasRelatedWork W1998197110 @default.
• W2030751454 hasRelatedWork W2013270686 @default.
• W2030751454 hasRelatedWork W2030751454 @default.
• W2030751454 hasRelatedWork W2183376808 @default.
• W2030751454 hasRelatedWork W2428348270 @default.
• W2030751454 hasRelatedWork W277709121 @default.
• W2030751454 hasRelatedWork W300828146 @default.
• W2030751454 hasRelatedWork W4239247807 @default.
• W2030751454 hasRelatedWork W18987839 @default.
• W2030751454 hasVolume "76" @default.

• next